improvement in the WHO-category ordinal scale by 2 points in moderate COVID-19 Ivermectin, Favipiravir, COVID-19, Treatment, Thailand
Conditions
Interventions
After laboratory result, intervention arm received ivermectin (at dose of 400 mcg/kg/day for 5 continuous days) plus standard of care which included favipiravir in moderately ill COVID-19 patients ,Co
Ivermectin Plus Favipiravir-Based Standard of Care versus Favipiravir-Based Standard of Care ,Controlled
Sponsors
Dr. Anucha Apisarnthanarak
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Moderate COVID-19 infection by RT-PCR technique 2. Date of onset <7 days 3. Admitted at Thammasat University hospital or Thammasat Field hospital
Exclusion criteria
Exclusion criteria: 1. Asymptomatic patient 2. Patient with severe symptom (on high flow nasal canular oxygen or above) 3. Pregnancy women 4. Lactating women 5. Chronic liver disease 6. Meningitis patient 7. Epilepsy who on barbiturate, benzodiazepine or valproic aside as medication 8. Who can't tolerate to oral feeding 9. Who participate other experimental drugs 10. Who had symptom that might mimicking severe drug adverse reaction (uncontrollable nausea/vomitting, liver function test 3 times UNL or above) 11. Who wish not to participate the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement in WHO-category ordinal scale by 2 points at day 3, 7, 14, 21 after treatment WHO-category ordinal scale | — |
Secondary
| Measure | Time frame |
|---|---|
| Duration of illness at day 3, 7, 14, 21 after treatment days,development of severe COVID-19 at day 3, 7, 14, 21 after treatment worsening in WHO-category ordinal scale by 2 points, requiring intensive care unit admission,Adverse reaction at day 3, 7 after treatment By questionnaire | — |
Countries
Thailand
Contacts
Public ContactPhahol Sarojvisut
Thammasat University
Outcome results
None listed